South Africa’s PEPFAR Funding Cuts Spark Concern Over HIV/AIDS Response

Text
The FW de Klerk Foundation has publicly urged former U.S. President Donald Trump to reconsider a proposed phased withdrawal of funding for the President’s Emergency Plan for AIDS Relief (PEPFAR) in South Africa, according to a statement released by the organization on June 21, 2026. The foundation, established in memory of South Africa’s first post-apartheid president, F.W. de Klerk, emphasized the potential health and economic consequences of the funding cuts, which it described as “deeply concerning.”

Subheading
What is PEPFAR and Why Does It Matter?
PEPFAR, launched in 2003, is a U.S. government initiative aimed at combating the global HIV/AIDS epidemic. In South Africa, the program has been a cornerstone of the country’s efforts to reduce HIV transmission and provide antiretroviral therapy to millions. According to the U.S. Agency for International Development (USAID), PEPFAR supported over 5.3 million South Africans with HIV treatment in 2025. The proposed funding reduction, part of broader U.S. budget realignments, has sparked debate over its impact on public health infrastructure and access to care.

Subheading
How Has the South African Government Responded?
South Africa’s Department of Health has called for “urgent and coordinated action” to address the potential shortfall, according to a statement from the ministry dated June 20, 2026. The government highlighted that PEPFAR funding covers critical services, including maternal health programs and community-based testing initiatives. “Any disruption could reverse decades of progress in curbing the HIV epidemic,” the statement said. The African National Congress (ANC) has also criticized the U.S. decision, with Health Minister Joe Phaahla warning that cuts could “undermine national health security.”

Subheading
What Are the Broader Implications?
The potential withdrawal of PEPFAR funding has drawn attention from international health organizations. The World Health Organization (WHO) noted in a June 18, 2026, report that South Africa accounts for nearly 20% of the global HIV burden, with an estimated 8.3 million people living with the virus. “Sustained investment is critical to achieving the 90-90-90 targets for diagnosis, treatment, and viral suppression,” the WHO statement said. Meanwhile, the U.S. Department of State has not yet commented on the specific funding proposal, though a spokesperson reiterated in a June 21, 2026, statement that “the administration remains committed to global health security.”

Subheading
How Has the Public and Civil Society Reacted?
Civil society organizations in South Africa have joined the call for continued support. The Treatment Action Campaign (TAC), a leading HIV advocacy group, released a statement on June 20, 2026, condemning the cuts as “a betrayal of vulnerable communities.” The group cited data showing that PEPFAR funding has enabled the expansion of community health worker programs, which have been vital in reaching rural populations. “Without this support, thousands could lose access to life-saving care,” said TAC spokesperson Lindiwe Mkhize.

Subheading
What Comes Next?
The U.S. Congress is expected to review the proposed budget adjustments in the coming months, with some lawmakers advocating for a “phased approach” to avoid abrupt disruptions. Meanwhile, the FW de Klerk Foundation has pledged to continue engaging with U.S. officials and South African stakeholders. “This is not just a matter of policy—it is a moral imperative,” said foundation chairperson Helen Zille in a June 21, 2026, interview. The foundation also announced plans for a series of public forums to discuss the issue, beginning in July 2026.

Text
South Africa’s health sector remains cautiously optimistic that diplomatic and financial negotiations could mitigate the impact of the proposed cuts. However, advocates stress that any delay in securing alternative funding could exacerbate existing challenges, including drug shortages and reduced testing capacity. As the debate continues, the role of PEPFAR in South Africa’s HIV response remains a focal point for global health policy discussions.